It's probably a non-issue since the Early-Phase Clinical Trial is dosing up to 30 healthy volunteers. I have been following NSB due to its focus on neurodegenerative diseases and hope to one day see it tested to see if it improves outcomes for these patients.
Ann: HREC decision to not approve Phase I Clinical Trial, page-76
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.639M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 465000 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 274977 | 3 |
View Market Depth
| Last trade - 16.00pm 10/10/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable